ArticleThe Journal of pharmacology and experimental therapeutics2022

Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.

Lloyd Wei Tat Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.